CRISPR Therap N
CRSP
USD
STOCK MARKET:
NMS
Closed
 
...
Large gap with delayed quotes
Last quote
11/04/2025 - 23:20:00
Bid
11/04/2025 - 21:59:58
Bid
Volume 		Ask
11/04/2025 - 21:59:58
Ask
Volume
56.41
-5.56 ( -8.97% )
56.37
700
56.39
100
More information
Analysis by TheScreener
31.10.2025
Evaluation Slightly negative  
Interest Weak  
Sensibility High  
Analysis date: 31.10.2025
Global Evaluation
  Slightly negative
The stock is classified in the slightly negative zone since 06.06.2025.
Interest
  Weak
Two stars since 31.10.2025.
Earnings Rev Trend
  Positive
 
Compared to seven weeks ago, the analysts have raised their earnings per share estimates. This positive trend began 17.10.2025 at a price of 69.15.
Evaluation
  Strongly overvalued
 
Based on its growth potential and our own criteria, we believe the share price is currently overvalued.
MT Tech Trend
  Neutral
 
The stock is currently trading close to its dividend-adjusted forty day moving average (changes between +1.75% and -1.75% are considered neutral). Prior to this, the stock traded above its moving average since 12.09.2025.
4wk Rel Perf
  -3.53%
 
The four-week dividend-adjusted underperformance versus SP500 is 3.53%.
Sensibility
  High
High, no change over 1 year.
Bear Market Factor
  High
On average, the stock has a tendency to amplify the drops in the index by 1.67%.
Bad News Factor
  Low
When the stock's pressure is specific, the market sanction on average is 4.01%.
Mkt Cap in $bn
  5.82
With a market capitalization between $2 & $8bn, CRISPR THERAPEUTICS is considered a mid-cap stock.
G/PE Ratio
  0
A negative ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) indicates that either the forecasted growth is decelerating (negative annualized growth estimate) or the financial analysts are expecting a loss (negative estimated PE).
LT P/E
  -18.68
The estimated PE is negative: the financial analysts' earnings estimates forecast a loss.
LT Growth
  -0.05%
The annualized growth estimate is for the current year to 2027.
Avg. Nb analysts
  23
Over the last seven weeks, an average of 23 analysts provided earnings per share estimates.
Dividend Yield
  0.00%
The company is not paying a dividend.
Beta
  153
For 1% of index variation, the stock varies on average by 1.53%.
Correlation
  0.44
44.24% of stock movements are explained by index variations.
Value at Risk
  31.36
The value at risk is estimated at USD 31.36. The risk is therefore 49.01%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
  08.09.2020